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Limited knowledge exists about development of bronchial hyperresponsiveness (BHR) through
adolescence. We aimed to assess changes in and risk factors for BHR in adolescence.
From a Norwegian birth cohort 517 subjects underwent clinical examinations, structured
interviews and methacholine challenges at age 10 and 16. BHR was divided into four cate-
gories: no BHR (cumulative methacholine dose required to reduce FEV1 by 20% (PD20)
>16 mmol), borderline BHR (PD20 16 and >8 mmol), mild to moderate BHR (PD20 8 and
>1 mmol), and severe BHR (PD20  1 mmol). Logistic regression analysis was used to assess risk
factors and possible confounders.
The number of children with PD20  8 decreased from 172 (33%) to 79 (15%) from age 10e16
(p < 0.001). Most children (nZ 295, 57%) remained in the same BHR (category) from age 10e16
(50% with no BHR), whereas the majority 182 (82%) of the 222 children who changed BHR cate-
gory, had decreased severity at age 16. PD20  8 at age 10 was the major risk factor for
PD20  8 6 years later (odds ratio 6.3), without significant confounding effect (>25% change)
of gender, active rhinitis, active asthma, height, FEV1/FVC, or allergic sensitization.
BHR decreased overall in severity through adolescence, was stable for the majority of chil-
dren and only a minority (8%) had increased BHR from age 10 to 16. Mild to moderate and
severe BHR at age 10 were major risk factors for PD20  8 at 16 years and not modified by
asthma or body size.
ª 2011 Elsevier Ltd. All rights reserved.Introduction characterized by episodes of excessive airway narrowing in
response to provoking stimuli1 Methacholine is a directBronchial hyperresponsiveness (BHR) is associated with
underlying chronic inflammation of the airways andsity Hospital, Department of Paed
no (A. Riiser).
1 Elsevier Ltd. All rights reservedmeasure of BHR through stimulation of the bronchial smooth
muscle.2 Most individuals may react with bronchialiatrics, NO-0407 Oslo, Norway. Tel.: þ47 23016751.
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Figure 1 Flow chart of the children included in the “Envi-
ronment and Childhood asthma study in Oslo” The overall
attendance rate at the 10 year follow-up was 84% while it was
45% at the 16 year follow-up.
Figure 2 Box plot of natural logarithm of methacholine
doseeresponse slope (LnDRS) at the age of 10 and 16 years.
n Z 517. The boxes show median values with 25 and 75%
percentiles, Whiskers show minimum to maximum values.
216 A. Riiser et al.constriction to inhaled methacholine provided a sufficiently
high dose,3 and a test is considered positive if a reduction in
forced expiratory volume in the first second (FEV1)  20%
occurs at any provocation dose (PD20) up to a pre-defined
level.4 However, the PD20 cut-off levels for defining BHR
varies.4 In addition to aid the diagnosis of asthma, BHR
assessed by direct provocation methods can be a prognostic
marker of asthma persistency and severity,5,6 and is used to
monitor long term treatment effects.7 Asymptomatic BHR
has been associatedwith development of asthma in children8
while others find no such association.9 BHR is associatedwith
age,10 reported to decrease trough childhood5,11,12 and to be
a risk factor for BHR later in life.12,13 Its been proposed that
gender,14 lung function,15 height16 and allergic sensitiza-
tion12 may influence the development of BHR.
The natural development of BHR through puberty must
be viewed in the context of its association with airways
disease and poorly understood underlying mechanisms.
The aims of the present study were therefore to deter-
mine how BHR assessed by methacholine challenge at 10
years of age was related to the BHR at age 16.
Subjects and methods
Design
The present study reports results from the 10- and 16-year
follow-up of children in the Environment and Childhood
Asthma study (ECA) in Oslo. This prospective birth cohort
established in Oslo, Norway in 1992 included 3754 healthy
newborn children of whom 803 had lung function
measured at birth17 and 306 cases (children with recurrent
bronchial obstruction by two years) and 306 controls
(children born closest in time to the cases but without
bronchial obstruction) were included for a two-year
investigation.18
The 10-year and 16-year follow-up studies (completed in
2005 and 2009, respectively) recruited the 1215 children
who had lung function measured at birth and/or a clinical
examination at two years of age (Figs. 1 and 2), and thus
represent an asthma-enriched general population.19
The 10- and 16-year follow-up studies included struc-
tured parental (10 years) and study subject (16 years)
interviews, skin prick tests (SPT), measures of lung function
and fractional exhaled nitric oxide (FeNO), as well as
methacholine provocation tests. All investigations required
at least 4 weeks free from symptoms of a respiratory tract
infection prior to the follow-up visits and no use of leuko-
triene antagonists for at least 72 h and short/long acting b-
2 agonists for at least 12/48 h respectively prior to the
methacholine tests.
The study was approved by the Regional Medical Ethics
Comity and the Norwegian Data Inspectorate, and registered
in the Norwegian Bio-Bank. Written informed consent was
obtained from all subjects’ parents at both investigations.
Subjects
At the 10-year follow-up study 1019 (84%) children attended
the investigation, whereas 550 (45%) attended the 16-year
study. However, 53% of the 10-year attendees wereexamined also at 16 years of age. The present study
comprised those 517 children (52% boys) who successfully
completed the methacholine challenges at 10 years of age
(mean 10.7, range 9.0e12.5) and 16 years of age (16.7,
15.7e17.5). Demographic data are given in Table 1.Methods
Except for the measures of BHR results from all tests are
reported from the 10-year follow-up investigation only.
Structured interviews were paediatrician-guided
towards the parents and included translated relevant
ISAAC questions of airway symptoms20 in addition to
detailed questions regarding lifestyle, disease and envi-
ronmental exposures (for details see supplement).
Definitions based upon the structured interview;
Active asthma: at least two out of three criteria ful-
filled: (1) doctor’s diagnosis of asthma, (2) the presence of
asthma symptoms during the last 12 months, (3) use of
asthma medication during the last 12 months.
Table 1 Characteristics of the 517 children completing the methacholine challenge at age 10 and 16 years, and the 502
children participating at the age of 10 years but not completing the methacholine challenge at the age of 16 years.
16 years 10 years,
participating at 16
10 years, not
participating at 16
P-value
10 vs. 10
P-value
10 vs. 16
Height, cm (SD) 173 (8.4) 145 (7.6) 146 (8.1) 0.06
Weight, kg (SD) 66.0 (11.3) 38.0 (7.7) 39.4 (8.5) 0.01
Age, years. months (range) 16.7 (15.7e17.5) 10.7 (9.0e12.5) 10.8 (8.8e12.5) <0.01
Boys, n (%) 270 (52) 270 (52) 279 (56) 0.29
Allergic sensitization, n (%) 252 (49) 132 (26) 162 (33) 0.01 <0.001
Active asthma, n (%) 88 (17) 54 (10) 60 (12) 0.37 <0.001
Asthma ever, n (%) 189 (37) 156 (30) 147 (30) 0.82 <0.001
Active rhinitis, n (%) 166 (32) 79 (15) 100 (20) 0.05 <0.001
ICS last 12 months, n (%) 47 (9) 37 (7) 48 (10) 0.16 0.17
Smoking at home, n (%) 48 (9) 68 (13) 82 (16) 0.13 0.02
Family history of asthma, n (%) 131 (25) 120 (23) 13 (26) 0.29 0.001
Family history of rhinitis, n (%) 46 (9) n/a n/a n/a n/a
EIA (n Z 466) n (%) n/a 75 (16) 79 (18) 0.27 n/a
ICS: Inhaled Corticosteroids, EIA: positive Exercise Induced Asthma test, SD: Standard Deviation, n/a: not available.
BHR decreases through childhood 217Active rhinitis: at least two out of three criteria fulfilled:
(1) doctor’s diagnosis of rhinitis, (2) present symptoms of
rhinitis during the last 12 months, (3) treatment for eye
nose or allergy symptoms during the last 12 months.
Lung function was measured by forced expiatory flow
volume loops according to European guidelines21,22 at 10
and 16 years of age using Sensormedics V-max (Sensor-
medics Diagnostics, Yorba Linda, CA, USA) spirometer.
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) are reported as raw values and % predicted23
and FEV1/FVC ratio (FEV1/FVC) as raw values only.
Fractional exhaled nitric oxide was measured with an
Eco Medics CLD 88 Exhalyzer (Eco Medics, AG 8635
Duernten, Switzerland) according to international
recommendations.24
Allergic sensitization was assessed by skin prick tests,
Soluprick (ALK Albello, Denmark), to 15 common inhalant
and food allergens according to European guidelines.25
Allergic sensitization was considered positive with a wheal
diameter of at least 3 mm (larger than the negative control)
to at least one common inhalant or food allergen (see
supplement for further details).
The exercise test was performed on a treadmill, 2e7
days after the methacholine challenge. The children ran for
6e8 min aiming at 95% of estimated maximum heart rate
during the last 4 min. A positive exercise test was defined as
a fall in FEV1  10% compared to baseline within 3e20 min
after exercise.26
A Methacholine challenge was used to assess BHR
according to ATS guidelines27 using a SPIRA dosimeter
(Spira Respiratory Care Center Ltd., Hemeenlinna, Fin-
land). Dose response slope (DRS) was calculated as maximal
% reduction in FEV1/cumulative dose methacholine admin-
istered and PD20 as the estimated cumulative methacholine
dose required to reduce FEV1 by 20% compared to baseline.
Based upon previously used cut-off values,4 we used the
main classification of no BHR or positive BHR as a PD20 >16
or 16 mmol, respectively.
Severity of BHR was classified into borderline BHR as
PD20 16 and >8 mmol, mild to moderate BHR as PD20 8and >1 mmol and severe BHR was defined as PD20 1 mmol.
(see supplement for further details).Outcomes, possible risk factors and explanatory
variables
The main outcome was a PD20  8 mmol methacholine,
classified as mild to moderate or severe BHR.
The main risk factors were; no BHR or positive BHR, as
well as the severity categories (no, borderline, mild to
moderate and severe BHR, respectively).
The main explanatory variables were active asthma,
active rhinitis, gender, allergic sensitization (as well to
a positive SPT to D. farinae and/or D. pteronnysinus),
height, exercise test, use of inhaled corticosteroids (ICS)
and lung function.Statistical analyses
Continuous variables are presented as mean (SD or range
when applicable), and categorical variables as count and
percentages. Student’s two-sample t-test was applied for
normally distributed variables andWilcoxoneManneWhitney
for non-normally distributed variables. For changes within
groups paired student’s t-test was applied. For categorical
variables Pearson’s Chi-Square for independent samples and
McNemar’s test for paired samples. In the multivariate anal-
ysis we applied logistic regression for binary outcomes. The
procedure used for the multivariate regression models was
Hosmer’s manually backward elimination technique28 Inter-
actions and model assumptions were inspected in the final
model and possible confounding effects were assessed
Nagelkerke R2 is given to describe the variation for the
outcomes explained by the risk factors.
Statistical Package for Social Sciences (SPSS) 15.0 for
Windows was used for statistical calculations. A p-value 
0.05 was considered statistically significant.
Figure 3 a: Bronchial hyperresponsiveness (BHR) in 517
children at the age of 10 and 16 years. Borderline BHR: PD20 >8
and 16 mmol, mild to moderate BHR: PD20 >1 and 8 mmol,
Severe BHR: PD20 1 mmol, years (yr). b: Changes in severity of
bronchial hyperresponsiveness (BHR) from the age of 10e16
years (n Z 517). Borderline BHR: PD20 >8 and 16 mmol, mild
to moderate BHR: PD20 >1 and 8 mmol, Severe BHR: PD20
1 mmol, years (yr).
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Demographics and data of personal and family history of
allergic diseases, skin prick test and exercise test are
given in Table 1 and results of lung function, DRS and
FeNO are given in Table 1 supplement. The included 517
children (52% boys) were largely representative for the
entire 10-year study group (Table 1), except for slightly,
but significantly younger age and lower weight as well as
being less often sensitized to allergens or reporting
active rhinitis compared to the 501 non-included
children.
Compared to the girls, the included boys were more
often sensitized to allergens, had more asthma (active and
ever), used more ICS, and had lower FEV1/FVC ratio and
higher DRS to methacholine at 10 years of age and taller at
the age of 16 years.
BHR at 10 and 16 years
Fifty per cent of all subjects (nZ 256) had positive BHR on
at least one occasion (Fig. 3a) and the number of children
with positive BHR decreased from 224 (43%) to 118 (23%)
(p < 0.001) from 10 to 16 years of age, respectively. The
corresponding number of children with a PD20  8 mmol
methacholine decreased from 172 (33%) to 79 (15%)
(p < 0.001).
The majority of subjects (nZ 295, 57%) remained in the
same BHR category from the 10e16 years investigation
(Fig. 3b), whereas most (82%) of the 222 subjects who
changed BHR category had decreased severity of BHR at the
16-years investigation; 138 lost their BHR altogether
(Fig. 3b).
Of the 39 children with increased bronchial responsive-
ness, 22 became hyperresponsive whilst 17 became
increasingly hyperresponsive. Significantly more girls than
boys (10.5 vs 5.6%) (p < 0.05) changed towards more severe
BHR, while more boys than girls (39.0 vs 30.6%) (p < 0.05)
changed to a less sever BHR category.
At 10 years of age boys had significantly more often
severe BHR than girls (p Z 0.002).
Risk of BHR at 16 years of age
In bivariate analysis PD20  8 mmol at the age of 10 years
was a significant risk factor for PD20  8 mmol six years later
(odds ratio (OR) 6.3 (3.7, 10.6)) for all children, explaining
17% of the variation of in BHR at 16 years of age, with ORs
9.9 (4.3, 22.6) and 4.5 (2.2, 9.1) for boys and girls respec-
tively. The corresponding values for PD20 16 mmol at 10
years are given in the supplement.
In the multivariate analysis including all BHR severity
categories and explanatory variables only mild to moderate
BHR, severe BHR, gender and FEV1/FVC remained signifi-
cant risk factors at 10 years of age for PD20 8 mmol at 16
years of age (Fig. 4). The confounding effect of the cova-
riates was negligible (<25%) in bivariate and multivariate
analysis (Table 3).
Stratified by gender, mild to moderate or severe BHR at
the age of 10 years were significant risk factors for mild to
moderate or severe BHR at the age of 16 years, explaining23% of the variation of BHR in boys and 12% in girls. The
highest risk for mild to moderate or severe BHR at 16 years
was found in boys with severe BHR at 10 years (Table 2).
Table 4 demonstrates cross sectional and longitudinal
bivariate associations between age, height or lung function
and PD20  8 mmol.
The current use of ICS was not associated with rate of
improvement in BHR severity category from 10 to 16 years
(81% vs 86% among children not using ICS (p Z 0.54)).Discussion
The present study demonstrated that the severity of BHR
overall decreased from 10 to 16 years of age. Although 57% of
the children were classified in the same BHR category at
both investigations, 82% of those who changed category, had
decreased severity. Positive BHR, mild to moderate BHR and
severe BHR at the age of 10 years increased the risk ofmild to
Figure 4 Final prediction model for mild to moderate or
severe BHR (PD20 8 mmol) at 16 years of age adjusted for at
active asthma, active rhinitis, gender, allergic sensitization,
height, exercise test, use of inhaled corticosteroids and FEV1/
FVC at the age of 10 years. Borderline bronchial hyper-
responsiveness (BHR): PD20 >8 and 16 mmol, mild to moderate
BHR: PD20 >1 and 8 mmol and severe BHR: PD20 1 mmol.
BHR decreases through childhood 219moderate or severe BHR six years later while borderline BHR
did not. Active asthma, active rhinitis, gender, height, lung
function and allergic sensitization at the age of 10 years did
not confound these associations. Reduced forced expiratory
flow values, were associated with current and future BHR,
whereas height or FVC were not.Bronchial responsiveness at the age of 10 and 16
years
The present study confirms that BHR decreases from
childhood to adolescents, as has been shown previously in
patient populations11,14 and general populations.5,9,12
Our findings of individual changes in BHR over a time
period of six years demonstrated that BHR was stable in
most subjects, but was reduced in more than 80% of those
changing BHR category. This is supported by one other
study reporting that 70% of those changing BHR status lost
their BHR.9 This supports the view that although BHR
decreases through childhood, it is a dynamic process that
can vary over time29 and may change with variousTable 2 The risk of having mild to moderate or severe
bronchial hyperresponsiveness at the age of 16 years with
different severity of bronchial responsiveness at the age of
10 years in 269 males and 248 females. The odds ratios are
based on bivariate relationships, and no bronchial respon-
siveness (PD20 > 16 mmol) is the reference. The odds ratios
are based on bivariate relationships, and no bronchial
responsiveness (PD20 > 16 mmol) is the reference.
Gender Risk factor OR 95% CI
Male Borderline BHR 1.8 0.3, 9.2
Male Mild to moderate BHR 4.8 1.7, 13.4
Male Severe BHR 50.7 16.3, 157.8
Female Borderline BHR 0.9 0.2, 4.2
Female Mild to moderate BHR 4.1 1.9, 8.8
Female Severe BHR 6.5 1.6, 25.7
BHR: Bronchial Hyperresponsiveness, severe BHR: PD20
1 mmol, mild to moderate BHR: PD20 8>1-mmol, borderline
BHR: PD2016>8 mmol, OR: Odds Ratio, CI: Confidence Interval.environmental exposures such as tobacco smoke, pollens,
temperature and airway infection.
The only gender difference in BHR was a male prepon-
derance of severe BHR at the age of 10 years (11% vs. 4%,
pZ 0.004), but significantly more girls than boys increased
their BHR from the age of 10 to the age of 16 years. This
may reflect the start of a shift towards more severe BHR in
post pubertal females as described by Tantisira et al.14 This
gender shift is further strengthened by the more
pronounced decrease in BHR in boys between the two
investigations in the present study. In contrast to Tantisira
et al.14 Paoletti et al.30 found more BHR in childhood girls
and in childhood-adolescent boys while other studies have
failed to discover gender difference in BHR.11 If the trend
of girls becoming more and boys becoming less responsive
continues and the follow-up was conducted at a later stage,
we might have experienced a gender difference in the BHR
categories similar to the findings in a recently published
study in mice demonstrating a gender related age differ-
ence in BHR with a male preponderance for BHR early in
life, and female preponderance later in life.31Risk of BHR at the age of 16
In the present study the different definitions of BHR (except
borderline BHR) at 10 years of age significantly increased
the risk of PD20 8 mmol 6 years later confirming the results
of Ulrik and Backer.12 and Roorda et al.13 reporting asso-
ciations between logarithmic doseeresponse to histamine
in childhood and BHR in adolescence and early adulthood.
Although allergic sensitization in general and to HDM in
particular significantly increased the risk of BHR six years
later in bivariate analyses, this was no longer significant
after relevant adjustments in the present study. This
reflects findings from other studies, where a positive skin
prick test has been associated with BHR in some32,33 but not
all studies.34 Allergic sensitization to HDM has as been
linked to BHR in cross sectional32,33 and longitudinal
studies12 and has been reported to be a risk factor in
childhood for BHR in adolescence even after adjusting for
asthma.15BHR, lung function and body size
There was no association (in cross sectional data) between
height and mild to moderate or severe BHR, even with
a height range of 47 cm and 50 cm, respectively. These
findings agree with those reported by Ownby et al.35 Crude
associations between height and BHR have been re-
ported,16,36 whereas after adjusting for FVC or FEV1/FVC
such associations appear to be non-significant.36 Our data
showed no significant association between height and mild
to moderate or severe BHR and FVC while Peat et al.36
reported a small but significant effect of FVC (in cross
sectional data among 1613 children aged 7e12 years).
Measures of airway obstruction as FEV1 (% predicted and l/
s) and FEV1/FVC were associated with BHR six years later,
similar to the findings of Ulrik and Backer12 but FEV1/FVC
was the stronger predictor and was used for the multivar-
iate prediction model in the present study.
Table 3 The risk of severe to moderate or severe bronchial hyperresponsiveness at the age of 16 years with different
categories of bronchial hyperresponsiveness at the age of 10 years and the confounding effect of active asthma, active rhinitis,
gender, allergic sensitization and FEV1/FVC.
Possible confounders Severe BHR Moderate to mild BHR Borderline BHR
Bivariate analysis
Crude, OR (95% CI) 21.8 (9.9, 48,1) 4.1 (2.2, 7.5) 1.1 (0.4, 3.5)
Active asthma, OR (change) 17.9 (18%) 3.8 (7%) 1.1 (0%)
Active rhinitis, OR (change) 18.5 (15%) 3.9 (5%) 1.1 (0%)
Gender, OR (change) 25.2 (þ16%) 4.2 (þ2%) 1.2 (þ9%)
Allergic sensitization, OR (change) 20.6 (5%) 4.0 (2%) 1.2 (þ9%)
FEV1/FVC, OR (change) 18.2 (16%) 3.9 (5%) 1.1 (0%)
Multivariate analysis
AA and AR, OR (change) 16.9 (23%) 3.8 (7%) 1.1 (0%)
AA, AR and gender, OR (change) 19.3 (12%) 3.8 (7%) 1.1 (0%)
AA, AR, gender, AS and FEV1/FVC, OR (change) 16.6 (24%) 3.5 (15%) 1.2 (15%)
BHR: Bronchial Hyperresponsiveness, severe BHR: PD20 1 mmol, moderate to mild BHR: PD20 8 and>1- mmol, Borderline BHR: PD20 16
and >8 mmol, OR: Odds Ratio, CI: Confidence Interval, AA: Active asthma, AR: Active Rhinitis, AS: Allergic sensitization: FEV1/FVC:
Forced Expiratory Volume in 1 s/Forced Ventilatory Capacity.
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mild to moderate or severe BHR and height or FVC as well as
no gender difference in BHR at 16 years of age (when boys
were taller than girls) in the present study. This questions
that the observed decrease in BHR is a result of somatic and
lung growth as was suggested by Le Souef et al.16 leading to
reduced constrictor-agent-dose to body-size ratio.Table 4 Cross sectional and longitudinal bivariate asso-
ciations between age, height or lung function and
PD20  8 mmol.
Explanatory
variables
Outcome OR 95% CI
Height 10y PD20  8 mmol 10y 1.00 0.98, 1.03
FVC 10y PD20  8 mmol 10y 0.85 0.54, 1.35
FEV1 l/s 10y PD20  8 mmol 10y 0.48 0.27, 0.86
FEV1 %
predicted 10y
PD20  8 mmol 10y 0.96 0.93, 0.98
FEV1/FVC 10y PD20  8 mmol 10y 0.49 0.36, 0.68
Age 10y PD20  8 mmol 10y 0.76 0.60, 0.95
Height 16y PD20  8 mmol 16y 0.99 0.97, 1.03
FVC 16y PD20  8 mmol 16y 0.92 0.71, 1.21
FEV1 l/s 16y PD20  8 mmol 16y 0.58 0.39, 0.86
FEV1 %
predicted 16y
PD20  8 mmol 16y 0.95 0.93, 0.98
FEV1/FVC 16y PD20  8 mmol 16y 0.50 0.43, 0.74
Age 16y PD20  8 mmol 16y 0.82 0.44, 1.56
Height 10y PD20  8 mmol 16y 1.00 0.97, 1.04
FVC 10y PD20  8 mmol 16y 0.99 0.97, 1.02
FEV1 l/s 10y PD20  8 mmol 16y 0.46 0.21, 0.99
FEV1 %
predicted 10y
PD20  8 mmol 16y 0.95 0.92, 0.98
FEV1/FVC 10y PD20  8 mmol 16y 0.44 0.29, 0.66
10y: 10 years of age, 16y: 16 years of age, OR: Odds ratio, CI:
Confidence interval, PD20: cumulative methacholine dose
required to reduce FEV1 by 20% compared to baseline, FEV1:
Forced Expiratory Volume in 1 s, FVC: Forced Ventilatory
Capacity.Rather, a progressive loss of compliance or increased
stiffness has been observed in other human tissues.37 A
similar development in the airway wall could increase the
mechanical load on airway smooth muscle and reduce
bronchial responsivenesswith age. This has to our knowledge
not been confirmed, but Wang et al. found no age related
change in airway mucosal membrane stiffness in rabbits.38
Strengths and limitations
The prospective design and the size of the study population
in the present study strengthen the validity of the results.
However, with only two measurement points, the possi-
bility for determining natural development in longitudinal
analyses is limited. With a follow-up rate of only approxi-
mately 50%, there is a risk that children with respiratory
problems may be over-represented in the last investigation.
However, such a case would lead to a possible underesti-
mation of the decrease in BHR and an over-estimation of
the risk estimates compared to a non-selected general
population. However, controlling for clinical characteristics
at 10 years revealed no significant differences between
those who did and did not attend the follow-up investiga-
tion. The attendees were in fact less often sensitized to any
allergen and had less often active rhinitis at 10 years of age
than those who did not attend the 16-year investigation.
Thus, it is likely that the results can be applicable to an
age-appropriate general population of children.
The definition of active asthma and active rhinitis in the
present study was based upon a structured clinical inter-
view39 and considered to be stricter then doctors diagnose
or questionnaire reported symptoms alone. The require-
ment of at last two out of three commonly used criteria
reduce the risk of over or under diagnosing asthma and
rhinitis.
Conclusion
The majority of children had the same level of BHR at the
age of 10 and 16 years, whereas 80% of those changing
BHR decreases through childhood 221category had reduced BHR. Although most categories of
BHR at 10 years of age were significant risk factors for mild
to moderate and sever BHR 6 years later, this was most
pronounced for severe BHR and not significant for border-
line BHR. Asthma, rhinitis, allergic sensitization and gender
did not modify these associations and the reduced BHR is
unrelated to changes in body size.
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